Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVie

Drug Profile

Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVie

Alternative Names: Cystic fibrosis therapy research programme - Cystic Fibrosis Foundation/Galapagos; GLPG-2665

Latest Information Update: 30 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 30 Oct 2018 Preclinical development in Cystic-fibrosis is ongoing in Belgium (PO)
  • 24 Oct 2018 AbbVie obtains exclusive worldwide rights to develop and commercialise therapies in Cystic fibrosis
  • 15 Oct 2015 Early research in Cystic fibrosis (Combination therapy) in Belgium (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top